Cantor Fitzgerald Reiterates Overweight Rating on Xenon Pharmaceuticals (XENE)
Tweet Send to a Friend
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating and $55.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
